HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Etoricoxib

HCID 123619
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
202409-33-4
Standard SMILES
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
InChIKey
MNJVRJDLRVPLFE-UHFFFAOYSA-N
Molecular formula
C18H15ClN2O2S
Average molar mass
358.8 g/mol
Monoisotopic mass
358.0542766

Overview

Etoricoxib is a member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively. It has a role as a non-steroidal anti-inflammatory drug and a cyclooxygenase 2 inhibitor. It is a sulfone, an organochlorine compound and a member of bipyridines.

Names & identifiers

Preferred name
Etoricoxib
IUPAC
5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridine
English name
Etoricoxib
Molecular formula
C18H15ClN2O2S
Molecular weight
358.84

Names & synonyms

Etoricoxib202409-33-4Arcoxia5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridineMK-06635-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridineetoricoxibumL-7914565-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridineDTXSID3046457MK06632,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-
Show more names
EtoricoxibeEtoricoxib APIAlgixEtocoxEtoxibMK 663TauxibEtobrix
WRX4NFY03R5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridineL7914562,3'-Bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridineCHEBI:6339DTXCID10264575-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl

Database identifiers

CAS
202409-33-4
PubChem CID
123619
DTXSID
DTXSID3046457
ChEMBL
CHEMBL416146
ChEBI
CHEBI:6339
UNII
WRX4NFY03R
EC Number
682-421-5
Nikkaji
J1.126.176K

Properties

Computed structural propertiesFilling in

XLogP
3.3
Topological polar surface area
68.3 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
4
Rotatable bonds
3
Heavy atoms
24
Formal charge
0
Complexity
514

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Solubility3.28e-03 g/L
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Anti-Inflammatory Agents, Non-Steroidal

Pharmaceuticals

Physical DescriptionSolid

Physicochemical properties

Melting point
134 · 134-135°C
Boiling point
510 · 510.0±50.0 °C(Predicted)
Density
1.298 · 1.298±0.06 g/cm3(Predicted)
storage temp.
2 · Inert atmosphere,2-8°C
solubility
100 mg/mL · DMSO : 100 mg/mL (278.68 mM; Need ultrasonic)
pka
4.5 · 4.5(at 25℃)
form
Solid
color
Light yellow to yellow
BRN
8073797 · 8073797
Major Application
forensics and toxicologypharmaceutical (small molecule)veterinary
InChI
InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
InChIKey
MNJVRJDLRVPLFE-UHFFFAOYSA-N
SMILES
C1(C2=CC=C(C)N=C2)=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1
CAS DataBase Reference
202409 · 202409-33-4(CAS DataBase Reference)
FDA UNII
4 NFY03R · WRX4NFY03R
NCI Drug Dictionary
Arcoxia
ATC code
1 AH05 · M01AH05
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Protein binding
92 % · 92%
Excreted unchanged in urine
1 % · <1%
Volume of distribution
120 Litres · 120 Litres
Biological half-life
22 · 22 / Unchanged
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
302 · H302-H310
Precautionary statements
262 · P262-P264-P270-P280-P301+P312-P302+P352+P310
Hazard Codes
T
Risk Statements
22 · 22-24
Safety Statements
36 · 36/37-45
RIDADR
2811 · UN 2811 6.1 / PGII
WGK Germany
3 · 3
Storage Class
6.1 A · 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
2 DermalAcute · Acute Tox. 2 DermalAcute Tox. 4 Oral

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (69.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P262, P264, P270, P273, P280, P301+P317, P302+P352, P316, P318, P319, P321, P330, P361+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 94 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (69.1%)

Toxicology

Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Etoricoxib

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
ridadr
UN 2811 6.1 / PGII
risk_code
22-24
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T
safety_code
36/37-45
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard statements
H302-H310
Hazard Classifications
Acute Tox. 2 DermalAcute Tox. 4 Oral
Precautionary statements
P262-P264-P270-P280-P301+P312-P302+P352+P310

Chemistry & industry

Pharmacology

ATC Code · 3 items

M01AH05

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding92%
PharmacodynamicsEtoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).
Mechanism of ActionLike any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.
Biological Half-Life22 hours
Metabolism/Metabolites · 2 items

Hepatic, primarily via CYP3A4.

Etoricoxib has known human metabolites that include 6-Hydroxymethyletoricoxib and Etoricoxib 1'-N'-oxide.

MeSH Pharmacological Classification · 2 items

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.

Absorption, Distribution and ExcretionBioavailability is 100% following oral administration.
Cellular LocationsCytoplasm
Metabolite PathwaysEtoricoxib Action Pathway

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >2500
Use ClassificationPharmaceuticals
Applications · 6 items

DescriptionEtoricoxib is a COX-2 inhibitor developed as a follow-up of rofecoxib for the treatment of osteoarthritis, rheumatoid arthritis, dysmenorrhoea, gout, ankylosing spondylitis and pain. Several processes describe the preparation of etoricoxib in 4 or 5 steps from 6- methylnicotinate. The key step is the novel pyridine construction using annulation of a ketosutfone with a vinamidinium synthon. In human whole blood, in vitro, the IC50 value obtained for inhibition of COX-2 is 1 .I μM as compared to 116 μM obtained for inhibition of COX-1. Thus, etoricoxib is the most selective COX-2 inhibitor to date, with a COX-IKOX- 2 ratio of IC50 values of 106 for etoricoxib as compared to 35, 30, 7.6 for rofecoxib, valdecoxib and celecoxib, respectively. Its in vivo potency is generally comparable to that of rofecoxib in animal models against inflammation (carrageenan-induced paw edema), pyrexia (LPS-induced pyresis), pain (carrageenan-induced hyperalgesia) and arthritis (adjuvant-induced arthritis). Etoricoxib is well tolerated with dose-proportional pharmacokinetics. It has no effect on bleeding time or platelet ag regation. The gastrointestinal tolerability of etoricoxib is excellent as demonstrated by [51Cr] models of excretion in rats and squirrel monkeys. Moreover, etoricoxib, unlike naproxen is not associated with significant inhibition of gastric mucosal PGE2 synthesis compared to placebo. Etoricoxib is highly absorbed, has a tmax of 1.5 h and a half-life time of approximately 15-22h. Five metabolites, weak inhibitors of COX-1 and COX-2 have been identified after renal excretion. Finally, although multiple CYP enzymes are involved in the metabolism of etoricoxib (CYP3A4 being the major contributor), etoricoxib is not a potent CYP3A4 inhibitor or inducer. In patients undergoing molar extraction, etoricoxib showed similar efficacy to naproxen sodium with a longer duration of analgesia than acetaminophen/codeine (approximately >24 h, 22 h and 5.2 h, respectively) and a better total pain relief score over 8 h. Similar efficacy of etoricoxib and naproxen was also seen in patients suffering of osteoarthritis. In the treatment of rheumatoid arthritis and ankylosing spondylitis, etoricoxib demonstrated significantly superior efficacy compared to naproxen and placebo. Etoricoxib did not affect the pharmacokinetics of prednisolone (i.v. or p.0.) and its co-administration with antacids showed insignificant effects on the maximal concentration and its absorption. .

Usesanti-inflammatory, analgesic;cyclooxygenase inhibitor

UsesFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

UsesLabeled Etoricoxib, intended for use as an internal standard for the quantification of Etoricoxib by GC- or LC-mass spectrometry.

UsesEtoricoxib is a dipyridinyl compound that demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays, e.g., in the production of PGE2 by CHO cells expressing either COX-2 (IC50 = 79 nM) or COX-1 (IC50 > 50 μM). Oral etoricoxib is well absorbed and metabolized extensively via oxidation, with metabolites excreted largely in the urine.[Cayman Chemical]

UsesA specific inhibitor of COX-2 .

Upstream & downstream products

Downstream products

5-Chloro-6'-Methyl-3-[4-(Methylsulfonyl)phenyl]-2,3'-bipyridine 1'-Oxide

Additional notes

DefinitionChEBI: A member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes